Long-term clinical outcomes of lipiodol marking using standard gastroscopy for image-guided radiotherapy of upper gastrointestinal cancers

Table 1 Patient demographics and treatment

Variables		Median/n	Range/%
	Age	77.4	57.5-88.0
	Male	20	64.5
Site of cancer	Oesophageal	21	67.7
	GOJ (Siewert I/II)	1	3.2
	GOJ (Siewert III)	2	6.5
	Gastric	7	22.6
Type of cancer	Oesophageal SCC	16	51.6
	Oesophageal adenocarcinoma	6	19.4
	Gastric adenocarcinoma	9	29.0
Endoscopy data	Patients with both proximal and distal fiducial placed	24	77.4
	Patients with solely proximal or distal fiducials placed	7	22.6
ECOG	0	13	41.9
	1	11	35.5
	2	7	22.6
Stages1	LN negative without distant metastasis	21	67.7
	LN positive without distant metastasis	6	19.4
	Distant metastasis present	3	9.6
Radiotherapy	Fiducial seen on CBCT	29	93.5
	Fiducial-based IGRT	27	87.1
Treatment intent	Neoadjuvant chemotherapy with oesophagectomy	3	9.7
	Definitive chemoradiotherapy	12	38.7
	Palliative chemoradiotherapy	3	9.7
	Definitive radiotherapy	8	25.8
	Palliative radiotherapy	5	16.1

¹Staging as per AJCC 8^th edition. T-stage was not available for all patients as endoscopic ultrasound is not routinely performed at our center.

SCC: Squamous cell carcinoma; ECOG: Eastern Cooperative Oncology Group; GOJ: Gastro-oesophageal junction; LN: Lymph Node; CBCT: Cone-beam computerized tomography; IGRT: Image-guided radiotherapy.